This YouthView study was published in 2019, communicating the results of a large, multi-country survey to assess the behaviours linked to meningococcal meningitis risk factors of adolescents and young adults in key European markets: France, Italy, Spain, Greece, and Portugal.
The YouthView (Understanding Risk Behaviours for Meningococcal Meningitis among Young People) survey is based on over 4,500 interviews among adolescents (15-17 years old), young adults (18-24 years old) and parents of adolescents and young adults. The interviews were conducted via an online survey between February and June 2018. The YouthView survey, sponsored by Pfizer Vaccines*, shows that across key European markets, there is a generally poor understanding about the risks for contracting meningococcal meningitis.
Sample quotas (based on 2011 Eurostat census data) were imposed to ensure national representation based on age, gender and region. Corrective weights have been applied to bring the sample in line with the population profile per country, as well as ensuring that each country is represented accordingly for all data points presented at a combined market level.
Ipsos MORI would now like to invite those interested to have full access to the wealth of findings included in our country reports and infographics.
Invasive meningococcal disease, which is caused by meningococcal bacteria, and primarily results in meningitis and/or septicaemia, is referred to here as ‘meningococcal meningitis’.
*Pfizer International Operations, RCS 491 295 671 Paris, France
 European Centre for Disease Control (ECDC). Surveillance of invasive bacterial diseases in Europe 2014. Available at: http://ecdc.europa.eu/en/publications/Publications/AER-VPD-IBD-2014.pdf. Accessed January 18, 2018.
 World Health Organization. Meningococcal meningitis, fact sheet No.141. Available at: www.who.int/mediacentre/factsheets/fs141/en. Updated November 2015. Accessed December 3, 2017.
 Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10(12): 853–861. Available here. Accessed January 18, 2018.
Five steps to ensure your evidence and access strategy is fit for the future
Our latest paper provides step-by-step guidance to launch strategies that are nuanced enough to capture value across stakeholders, supported by the right evidence at the right time and fit for a variety of future scenarios.
[EVENT] 2019 Corporate Reputation Salon in San Francisco
September 26 - Each year, the Ipsos Global Corporate Reputation practice conducts interviews with over 150 leading communications and reputation executives globally to understand the trends, issues and concerns facing today’s reputation practitioners.
[WEBINAR] The Future of Beauty: thriving across the consumer decision journey
The Beauty industry is now more fragmented and disrupted than ever in history. Beauty companies are challenged to stay ahead and lead the trends, as well to best predict whether or not they’ve developed the next biggest innovation.
[EVENT] The State of Reputation in Canada: Today’s Context, Tomorrow’s Expectations
On May 7, please join Ipsos for an exclusive breakfast presentation about the state of reputation in Canada – how companies are performing now, the impact of the current social and economic context on trust, and how your stakeholder’s future hopes and expectations will influence your reputation in the years to come.